الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 232 |  |  |
| | | from | 232 | | |
Abstract
This study aimed to: Investigate the diagnostic value of CD49d expression surface protein marker in patients with CLL and its relation with other markers such as (CD5, CD19). Also, its relation with some antioxidants as well as the correlation with disease progression in patients with CLL. The results obtained in this current study showed that: • There wasstatistically significant increase of CD49d expression in CLL patients when compared to normal control subjects. • The mean percentages of CD19 and/or CD5 expression positive cells was significantly higher in CLL than in normal peripheral blood and CD49d expression of the relevant CD5/CD19 double positive cells in CLL patient but in normal control was significantly different. • There was a significant association between progression to a more advanced stage and high CD49d expression and so the higher CD49d expression was found to be associated with increased risk of CLL and disease progression. • There were significantly increase in plasma catalase (CAT) activity, erythrocyte lysate reduced glutathione (GSH) and plasma malondialdehyde (MDA) concentration in CLL patients when compared to control group. from this study, we concluded that: • Measurement of CD49d expression may have a promise therapeutic implications and represents as tractable drug targets marker for therapeutic approaches in B-CLL patients and so, CD49d evaluation could be used as predictive test for treatment and disease outcome.CD49d have the potential to significantly improve the clinical management of CLL patients. 4 • The determination of antioxidant enzyme activities may be useful for early diagnosis of CLL patients and for assessment of progression of the disease tumor. Additionally, they have a good prognostic relevance and so, may be applied as predictive factors for prediction of clinical disease outcomes and progression of CLL disease.